Sarepta Therapeutics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$116.9M
Doctors Paid
1,587
Transactions
21,423
2024 Total
$17.2M
Payment Breakdown by Category
Research$103.9M (88.9%)
Consulting$6.0M (5.1%)
Royalty/License$4.5M (3.8%)
Travel$927,060 (0.8%)
Food & Beverage$193,459 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $103.9M | 13,971 | 88.9% |
| Consulting Fee | $6.0M | 1,201 | 5.1% |
| Royalty or License | $4.5M | 64 | 3.8% |
| Grant | $1.2M | 53 | 1.0% |
| Travel and Lodging | $927,060 | 1,773 | 0.8% |
| Food and Beverage | $193,459 | 4,224 | 0.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $137,054 | 75 | 0.1% |
| Education | $16,385 | 60 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $2,545 | 2 | 0.0% |
Payments by Type
Research
$103.9M
13,971 transactions
General
$13.0M
7,452 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| 4045-301 | $21.0M | 3 | 903 |
| 4658-301 | $13.0M | 0 | 501 |
| SRP-9001-301 | $12.3M | 0 | 5,501 |
| SRP-9001-102 | $5.8M | 1 | 139 |
| SRP-9001-103 | $5.7M | 2 | 1,213 |
| SRP-5051-201 | $3.0M | 0 | 211 |
| SRP-9001-303 | $3.0M | 15 | 2,164 |
| Nationwide SRA | $3.0M | 0 | 14 |
| 4658-203 | $2.2M | 0 | 90 |
| 5051-201 | $1.9M | 1 | 141 |
| 4658-402 | $1.7M | 1 | 225 |
| 9001-102 | $1.5M | 0 | 10 |
| SRP-9001-305 | $1.3M | 0 | 833 |
| 4658-403 | $1.3M | 0 | 538 |
| 4045-101 | $1.2M | 2 | 57 |
| 4658-202 | $1.2M | 0 | 72 |
| 5051-102 | $1.2M | 0 | 206 |
| Research Institute at Nationwide SRA | $1.1M | 0 | 6 |
| 4658-204 | $986,509 | 0 | 43 |
| Leveraging large-scale genomic and clinical data to characterize rare, pathogenic mutations associated with dilated cardiomyopathy | $919,598 | 0 | 3 |
| SRP-LGMD-501-NHS | $916,841 | 0 | 131 |
| SRP-9003-301 | $898,996 | 1 | 91 |
| Sponsored Research Agreement - DMD | $852,155 | 0 | 31 |
| SRP-9003-102 | $613,033 | 0 | 37 |
| Phase IV Golodirsen | $595,541 | 0 | 4 |
| SRA with Duke for exosome gene editing | $563,500 | 0 | 2 |
| TESTING SARCOSPAN AS A THERAPEUTIC AND BIOMARKER FOR SARCOGLYCA | $487,797 | 0 | 3 |
| Powell Gene Therapy | $479,977 | 0 | 3 |
| Gene therapy approach to treat arrhythmias using MYBPC3 | $445,069 | 0 | 2 |
| Sponsored Research Agreement - CMT | $430,473 | 0 | 20 |
Payments by Medical Specialty
Top Paid Doctors — Page 3
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Nizar Chahin, M.d, M.D | Neurology | Portland, OR | $28,855 | $0 |
| Dr. Paul Watkins, Md, MD | Gastroenterology | Chapel Hill, NC | $27,645 | $0 |
| Susan Matesanz, Md, MD | Neurology with Special Qualifications in Child Neurology | Philadelphia, PA | $26,651 | $0 |
| Stanley Nelson, Md, MD | Pediatrics | Los Angeles, CA | $25,416 | $0 |
| Dr. Amal Aqul, Md, MD | Pediatrics | Dallas, TX | $25,242 | $0 |
| Cuixia Tian, M.d, M.D | Pediatrics | Cincinnati, OH | $25,145 | $0 |
| Jeremy Shefner, M.d, M.D | Neurology | Phoenix, AZ | $25,000 | $0 |
| Dr. Sanjay Kaul, M.d, M.D | Specialist | Los Angeles, CA | $25,000 | $0 |
| Dr. Jonathan Strober, M.d, M.D | Pediatrics | San Francisco, CA | $22,351 | $0 |
| Dr. Keith Kocis, Md, MD | Pediatric Critical Care Medicine | Falls Church, VA | $22,000 | $0 |
| Dr. Seth Perlman, Md, MD | Neuromuscular Medicine | Seattle, WA | $21,823 | $0 |
| Paul Lipkin, Md, MD | Neurodevelopmental Disabilities | Baltimore, MD | $21,113 | $0 |
| Omer Abdul Hamid | Neuromuscular Medicine | Orlando, FL | $20,822 | $0 |
| Tulio Bertorini, Md, MD | Neurology | Memphis, TN | $20,808 | $0 |
| Megan Waldrop, Md, MD | Pediatrics | Columbus, OH | $20,783 | $0 |
| Abigail Schwaede, Md, MD | Neuromuscular Medicine | Chicago, IL | $20,767 | $0 |
| Avram Traum, M.d, M.D | Pediatric Nephrology | Boston, MA | $20,125 | $0 |
| Stanton Gerson, Md, MD | Hematology & Oncology | Cleveland, OH | $20,000 | $0 |
| Saunder Bernes, M.d, M.D | Neurology with Special Qualifications in Child Neurology | Phoenix, AZ | $19,384 | $0 |
| Natalie Katz, M.d., Ph.d, M.D., PH.D | Internal Medicine | Durham, NC | $19,339 | $0 |
| Vamshi Rao, Md, MD | Neurology with Special Qualifications in Child Neurology | Chicago, IL | $18,474 | $0 |
| Dr. Vikki Stefans, M.d, M.D | Pediatric Rehabilitation Medicine | Little Rock, AR | $18,293 | $0 |
| Kathryn Wagner, M.d, M.D | Neurology | Baltimore, MD | $18,209 | $0 |
| Dr. Sarah Wright, D.o, D.O | Neurology with Special Qualifications in Child Neurology | Washington, DC | $17,760 | $0 |
| Susan Iannaccone, Md, MD | Neurology | Dallas, TX | $17,551 | $0 |
Ad
Top Products
- EXONDYS 51 $10.8M
- Exondys 51 $6.1M
Associated Products (5)
- EXONDYS 51 $10.8M
- Exondys 51 $6.1M
- Amondys 45 $4.8M
- Vyondys 53 $2.8M
- Elevidys $377,981
Payment Categories
- Food & Beverage $193,459
- Consulting $6.0M
- Travel & Lodging $927,060
- Research $103.9M
- Royalties $4.5M
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. has made $116.9M in payments to 1,587 healthcare providers, recorded across 21,423 transactions in the CMS Open Payments database. In 2024, the company paid $17.2M. The top product by payment volume is EXONDYS 51 ($10.8M).
Payments were distributed across 101 medical specialties. The top specialty by payment amount is Neurology with Special Qualifications in Child Neurology ($2.0M to 155 doctors).
Payment categories include: Food & Beverage ($193,459), Consulting ($6.0M), Research ($103.9M), Travel & Lodging ($927,060), Royalties ($4.5M).
Sarepta Therapeutics, Inc. is associated with 5 products in the CMS Open Payments database, including EXONDYS 51, Exondys 51, and Amondys 45.